Abbott has introduced its new Proclaim DRG Neurostimulator System in the US for reducing pain in patients with complex regional pain syndrome (CRPS) of the lower limbs such as the foot, knee and hip.
With new patient-centric benefits, the magnetic resonance (MR) conditional system delivers stimulation to the dorsal root ganglion (DRG).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The device is recharge-free and upgradeable with enhanced battery capacity, while it uses the Apple iPod touch mobile digital device as its patient communication controller through a Bluetooth wireless technology.
According to findings from clinical studies such as ACCURATE, DRG stimulation could deliver better pain relief in CRPS patients when compared to standard spinal cord stimulation (SCS) therapy.
It was also observed that DRG stimulation allowed patients to achieve better therapeutic targeting and a decrease in paresthesia, compared with traditional tonic SCS.
ACCURATE study co-principal investigator and Spine and Nerve Centre of the Virginias interventional pain physician, president and chief executive officer Timothy Deer said: “Both clinical and real-world data have shown that DRG stimulation produces long-term, meaningful pain relief for patients with complex regional pain syndromes like those resulting after total knee arthroplasty, foot surgery or hernia surgery.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The ability to offer DRG stimulation on the Proclaim platform is a very exciting advancement for those of us who treat patients with these debilitating conditions and want to provide relief from hard-to-treat neuropathic conditions.”
Patients with the Proclaim DRG system are eligible to undergo magnetic resonance imaging (MRI) in scanners up to 1.5T.
